Want to see JP:4598 full AI Analyst Report?
4598 Stock Chart & Stats
¥106.00
-¥3.00(-2.88%)
At close: 4:00 PM EDT
¥106.00
-¥3.00(-2.88%)
Day’s Range― - ―
52-Week Range¥92.00 - ¥700.00
Previous CloseN/A
Volume217.10K
Average Volume (3M)1.13M
Market Cap
¥2.06B
Enterprise Value¥1.72K
Total Cash (Recent Filing)¥83.33M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-135.25
Shares Outstanding16,209,000
10 Day Avg. Volume3,124,130
30 Day Avg. Volume1,129,816
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)66.43
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt reduces mandatory interest and principal payments, which lowers leverage-related financial risk and preserves flexibility compared with a similarly loss-making company carrying borrowings. This provides some balance-sheet protection even though the remaining capital base is severely depleted.
Reported EPS GrowthThe reported positive EPS-growth metric indicates some improvement in the earnings measure used by the dataset, offering a limited constructive signal. However, its durability is uncertain because the company continues to report substantial net losses and has not restored revenue.
Historical Revenue GenerationThe company has previously generated meaningful reported revenue, showing that its operations have produced sales rather than remaining entirely pre-revenue throughout the period. That historical base is a modest strength, although it has not translated into continuing revenue in later fiscal years.
Bears Say
Revenue Has Fallen To ZeroRevenue remaining at zero for four fiscal years indicates a severe and sustained breakdown in commercial activity. Without recurring sales, the company lacks operating inflows to support research, administration, and future development, increasing dependence on external funding over the next several quarters.
Persistent And Worsening LossesLarge losses that have persisted and worsened demonstrate that the current cost base is not being covered by operating revenue. Continued negative profitability can consume remaining capital, constrain investment choices, and make financial stabilization dependent on a material improvement in operations or additional funding.
Severe Cash Burn And Capital ErosionOngoing cash outflows combined with a sharply reduced equity cushion materially weaken financial resilience. Persistent burn leaves fewer internal resources to fund development and increases the importance of securing capital, while the depleted balance sheet provides less capacity to absorb further losses.
Delta-Fly Pharma, Inc. News
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥92.00 and its highest was ¥700.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥2.06B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 67 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Delta-Fly Pharma, Inc. released its earnings results on Aug 07, 2026. The company reported -¥30.23 earnings per share for the quarter.
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 16,209,000 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Delta-Fly Pharma, Inc. reported an EPS of -¥30.23 in its last earnings report. Following the earnings report the stock price went down -0.926%.
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.